Tyrosine kinase inhibitorInvestigationalInvestigational
Regorafenib ( investigational combination )
Generic name: regorafenib
How it works
Regorafenib blocks multiple tyrosine kinases involved in cancer cell growth and angiogenesis.
Cancer types
Colorectal Cancer— All patients
Efficacy
Clinical trials are ongoing to evaluate the efficacy of regorafenib in combination with other agents in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Treatment for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Regorafenib Concentrations Linked to Survival in Colorectal Cancer Patients | Colorectal Cancer | phase-2 | Patients with a C2/C1 M-2 ratio ≥ median had improved survival compared to those < median (12.6 versus 4.0 months, P = 0.023), corresponding to a 66% mortality risk reduction in multivariate analysis. | Source → |
| Early Blood Test Predicts Effectiveness of Cancer Treatment | Colorectal Cancer | phase-2 | The early increase of Angiopoietin-2 was associated with a hazard ratio of 0.57 for progression-free survival and a trend towards longer overall survival. | Source → |
| Comparing Two Cancer Drugs in Real-World Patients | Colorectal Cancer | observational | No difference was observed for median time-to-treatment failure (regorafenib 2.7 months vs. fruquintinib 3.1 months, P = .200) or median overall survival (regorafenib 13.8 months vs. fruquintinib 11.3 months, P = .527). | Source → |
| New Biomarker for Colorectal Cancer Treatment Response Identified | Colorectal Cancer | phase-2 | Patients with baseline cfDNA > 26 ng·mL had shorter OS than those with cfDNA value below this threshold (4.0 vs 6.9 months; log-rank P = 0.0366). Patients with baseline mutant ctDNA > 2 ng·mL had shorter OS than those with mutant ctDNA below this threshold (log-rank P = 0.0154). | Source → |
| Trifluridine/Tipiracil Shows Promise for Metastatic Colorectal Cancer Patients | Colorectal Cancer | observational | The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. | Source → |
| New Compound Shows Promise in Treating Colorectal Cancer | Colorectal Cancer | lab-study | The compound was 14.5 times more potent than Regorafenib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.